Delcath grows in preparation for market launch
This article was originally published in Clinica
Delcath Systems, a company developing a drug delivery system for treating liver cancer, has expanded its management team with the following appointments: effective November 2, Armand "Chuck" Frigon will become vice-president of operations and Agustin Gago will assume the role of executive vice-president of global sales and marketing. John Purpura will join as executive vice-president of regulatory affairs and quality assurance on November 16. The New York company created these new roles as it moves closer to submitting its Delcath PHP system, designed for the regional delivery of melphalan to the liver, to the FDA for approval and initiating international licensing and manufacturing activities. Before joining Delcath, Mr Frigon was general manager of Sterigenics International; Mr Gago was vice-president of international oncology surgery sales at AngioDynamics; and Mr Purpura was most recently head of regulatory affairs, North and Latin America, at E-Z-EM.